Sentence examples for a single agent for from inspiring English sources

Most patients in the trial weren't helped by the drug and it was abandoned as a single agent for bladder cancer.

The initial SAT was based on a single agent for most patients (Table 2; Additional file 1: Doses of antifungal agents).

RITUXAN product is indicated for treatment of relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) as a single agent; for previously untreated diffuse large B-cell, CD20-positive, NHL in combination with CHOP or other anthracycline-based chemotherapy regimens; and for previously untreated follicular.

While a phase I trial indicated that CPI-613 may be effective as a single agent for treating hematological malignancies, a phase II trial for small cell lung carcinoma show no efficacy as a single agent (Pardee et al., 2014; Lycan et al., 2016).

AG-221 is an orally available inhibitor of mutant IDH2-R140 and IDH2-R172 (Yen et al., 2017), and is currently undergoing phase I/II clinical trials as a single agent for the treatment of AML and solid tumors (e.g., glioma and angioimmunoblastic T-cell lymphoma; NCT01915498 and NCT02273739, respectively).

While our studies indicate that ATRA is unsuitable as a single agent for expansion of human Tregs, a case can be made for the combined use of RAPA and ATRA.

However, the recent international literature is not very encouraging in the use of vasopressin as a single agent of choice for cardiac arrest.

These results provided the preclinical rationale for alisertib to enter phase II clinical trials, either as a single agent (NCT01154816, for neuroblastoma and sarcomas), or in combination with temozolomide and irinotecan (NCT01601535, for neuroblastoma).

Thus the cells became dependent on a single agent, IGF1, for survival under serum starvation.

Dabrafenib is a specific BRAF V600 inhibitor (BRAFi) approved by the US FDA as a single agent treatment for unresectable or metastatic melanoma in patients with the BRAF V600E mutation as detected by an FDA-approved test [ 36].

Despite prior exposure to anthracycline therapy, patient remission was obtained in up to 47% using vinorelbine as a single agent, and for anthracycline-resistant cancers a response rate of 16% was still achieved (Kroger et al, 1999).